CharlesNatansonMD

Critical Care Medicine

Adjunct Professor, Anesthesiology, University of Maryland School of Medicine

Are you Dr. Natanson?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 65 invites waiting!
Read the latest clinical news, personalized to your specialty.

Office
1150 Varnum St Ne
Washington, DC 20017
Phone+1 202-269-4000

Fax+1 202-269-7825

Dr. Charles Natanson, MD is a board certified anesthesiologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Maryland, and California. He is affiliated with Providence Hospital and is an Adjunct Professor at University of Maryland School of Medicine.

University of California (San Francisco)Residency, Anesthesiology, 1981 - 1983
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1977 - 1980
Columbia University Vagelos College of Physicians and SurgeonsClass of 1977

PubMed

HES IV Solutions Recall Pushed by Consumer Group over Injury ClaimsJuly 18th, 2017
Deadly IV Fluid Still Being Used Despite Known RisksJuly 26th, 2017

The Effect Of Glucocorticoids In A Sedated And Ventilated Model Of Canine SepsisClinical Center2007–2008
Development Of A Mechanically Ventilated And Sedated Model Of Canine Septic ShocClinical Center2007–2008
Tyrphostin AG 556 Therapy Adjusted To Severity Of IllnesClinical Center2001–2005
Investigations Of New Therapies In Septic ShockClinical Center1991–2005
Effect Of Nitric Oxide Synthase Inhibitors In Vivo TumorClinical Center2002
A Controlled Trial Of Tyrosine Kinase Inhibitors In A CAClinical Center2001–2002
Nitric Oxide In Myocardial DepressionClinical Center2001
Effect Of Reconstituted High-Density Lipoproteins In A CClinical Center2001
Tyrphostin AG 556 Therapy Adjusted To Severity Of Illness Of New Therapies In SEClinical Center2000
A Controlled Trial Of Tyrosine Kinase Inhibitors In A Canine Model Of Septic ShoClinical Center2000
Effect Of Nitric Oxide Synthase Inhibitors In Vivo Tumor Necrosis Factor-InducedClinical Center1998–2000
Tyrphostin AG 556 Therapy Adjusted To Severity Of Illness Of New Therapies In SEPClinical Center1998–1999
A Controlled Trial Of Tyrosine Kinase Inhibitors In A Canine Model Of Septic ShocClinical Center1998–1999
Investigations Of New Therapies In Septic ShockClinical Center1989–1990